What is the recommended atropine dosing regimen for organophosphorus poisoning in adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Atropine Dosing for Organophosphorus Poisoning

For life-threatening organophosphate poisoning, administer atropine immediately with an initial dose that is doubled every 5 minutes until full atropinization is achieved (clear chest on auscultation, heart rate >80/min, systolic blood pressure >80 mm Hg), then maintain with continuous infusion. 1

Initial Dosing Strategy

Adults

  • Start with 2-3 mg IV as initial bolus for severe poisoning with bronchospasm, bronchorrhea, seizures, or significant bradycardia 2
  • Double the dose every 5 minutes until atropinization endpoints are reached 1, 3
  • Much larger doses than typical bradycardia treatment are required—patients may need 23-75 mg or more in the first hours 4, 5
  • The FDA label recommends 2-3 mg initially, repeated every 20-30 minutes as needed 2

Pediatric Patients

  • Initial dose: 20-50 mg/kg (not the typical 0.01-0.03 mg/kg used for other indications) 1
  • Apply the same doubling strategy every 5 minutes until atropinization 3
  • For children >1 year with nerve agent exposure, full adult autoinjector doses (2 mg from Mark 1 kit) are appropriate when precise dosing is impossible 6

Atropinization Endpoints

Achieve all three of the following before reducing dosing 1:

  • Clear chest on auscultation (resolution of bronchorrhea and bronchospasm)
  • Heart rate >80 beats/min
  • Systolic blood pressure >80 mm Hg

Maintenance Therapy

  • Continuous infusion at 10-20% of the loading dose per hour once atropinization is achieved 1
  • Typical maintenance ranges from 0.005-0.06 mg/kg/h depending on severity of acetylcholinesterase inhibition 7
  • When RBC-AChE activity is 10-30% of normal, approximately 0.005 mg/kg/h maintains therapeutic levels 7
  • When RBC-AChE is completely inhibited, doses up to 0.06 mg/kg/h may be required 7

Critical Implementation Points

Rapid Escalation is Essential

  • Modern guidelines emphasize aggressive, rapid atropinization compared to older regimens that took hours to days 4
  • Current evidence-based regimens can achieve adequate atropinization within 30-60 minutes, compared to historical approaches requiring 18+ hours 4
  • Early atropine administration improves survival in clinical trials of life-threatening organophosphate poisoning 1, 3

Common Pitfalls to Avoid

Do not underdose atropine 4, 5:

  • The most common error is using doses appropriate for typical bradycardia rather than the supraphysiologic doses required for cholinergic crisis 3
  • Some patients require cumulative doses exceeding 100 mg in the first 6 hours 8

Monitor for inadequate response 8:

  • If target heart rate is not achieved despite 100 mg cumulative dose in 6 hours or 30 mg/h infusion for 3 hours, consider adding adrenaline infusion at 2-4 μg/min 8
  • Inadequate response is associated with shorter time to hospital presentation and requires longer ventilation duration 8

Watch for late complications 7:

  • Malignant arrhythmias can occur when S-hyoscyamine concentrations fall below 2.5 nmol/L, often in the absence of obvious cholinergic signs 7
  • These typically resolve with reinstitution of atropine 7

Adjunctive Therapy

Pralidoxime (Oximes)

  • Reasonable to administer for organophosphate poisoning (Class 2a recommendation) 1
  • Adults: 1-2 g loading dose, then 400-600 mg/h continuous infusion 1
  • Pediatric: 20-50 mg/kg loading dose, then 10-20 mg/kg/h infusion 1
  • Must be given early before "aging" of the organophosphate-enzyme complex occurs 1
  • Clinical efficacy remains uncertain in meta-analyses, with no mortality benefit demonstrated and possible increased incidence of intermediate syndrome 9

Other Essential Interventions

  • Benzodiazepines (diazepam first-line or midazolam) for seizures and agitation (Class 1 recommendation) 1
  • Early endotracheal intubation for life-threatening poisoning improves outcomes (Class 1 recommendation) 1, 3
  • Dermal decontamination with removal of clothing and copious soap/water irrigation (Class 1 recommendation) 1, 3
  • Personal protective equipment for healthcare workers to prevent secondary contamination (Class 1 recommendation) 1

Special Considerations

Coronary Artery Disease

  • Limit total atropine dose to 0.03-0.04 mg/kg in patients with known coronary disease to minimize risk of myocardial ischemia 2
  • This creates a clinical dilemma requiring careful risk-benefit assessment in severe poisoning

Atropine Tolerance

  • Atropine overdose is generally well tolerated in children, supporting the use of higher doses when needed 6
  • The elimination half-life of S-hyoscyamine is approximately 1.5 hours, with occasional secondary slow phase of 12 hours 7

Carbamate Poisoning

  • Use identical atropine dosing strategy as for organophosphates 1, 3
  • Carbamates spontaneously dissociate from acetylcholinesterase, so oximes may not be necessary, but should not be withheld when the specific poison class is unknown 1

References

Research

Comparison of current recommended regimens of atropinization in organophosphate poisoning.

Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.